MICHIGAN DEPARTMENT OF NATURAL RESOURCES

INTEROFFICE COMMUNICATION

October 21, 1994

TO:

File for Tolazamide (1156-19-0)

FROM:

Marco Bianchi

SUBJECT:

Initial Threshold Screening Level

The initial threshold screening level (ITSL) for tolazamide is 17 $\mu g/m^3$ based on an annual averaging time.

The following references or databases were searched to identify data to determine the ITSL: IRIS, HEAST, NTP Management Status Report, RTECS, EPB-CCD, EPB library, CAS-online, NLM-online, IARC, NIOSH Pocket Guide, and ACGIH Guide.

A complete reference check was conducted for tolazamide, but only limited information was available. Upjohn provided an in-house oral and IP $\rm LD_{50}$ study for tolazamide on mice and rats, respectively. The mouse IP study revealed a calculated IP $\rm LD_{50}$ of 2239 mg/kg, with total mortality at 3200 mg/kg (10/10).

In contrast, five groups of five rats per group were given a single oral dose of 2000, 2500, 3200, 4000, and 5000 mg/kg body weight of tolazamide suspended in 1% CMC vehicle. No deaths were observed for any of the test animals, and only salivation was noted in dose groups 2500 mg/kg and higher. To verify using 5000 mg/kg as a surrogate LD $_{50}$, the lowest human therapeutic dose (Physicians Desk Reference, 1994) was calculated for comparison. This calculation showed that 5000 mg/kg can be appropriately used for ITSL derivation.

The ITSL was derived as follows:

The LD_{50} for this study was determined to be 5000 mg/kg.

The ITSL was derived as follows:

 $LD_{50} = 5000 \text{ mg/kg}$

0.0166 mg/kg x 1000 = 16.6 or 17 μ g/m³ based on annual averaging.

The ITSL for tolazamide = 17 $\mu g/m^3$ based on annual averaging.

MB:ma